TY - JOUR T1 - Covid-19 Incidence And Mortality By Age Strata And Comorbidities In Mexico City: A Focus In The Pediatric Population JF - medRxiv DO - 10.1101/2021.06.21.21259282 SP - 2021.06.21.21259282 AU - Nadia González-García AU - María F Castilla-Peón AU - Fortino Solórzano Santos AU - Rodolfo Jiménez Juárez AU - Maria Elena Martínez Bustamante AU - Miguel Angel Minero Hibert AU - Juan Garduño-Espinosa Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/15/2021.06.21.21259282.abstract N2 - Background SARS-COV2 appears less frequently and less severely in the pediatric population than in the older age groups. There is a need to precisely estimate the specific risks for each age group to design health and education policies suitable for each populationObjective This study aimed to describe the risk of death in SARS-COV2 infected subjects by age group and according to the presence of comorbidities.Methods We analyzed data of confirmed SARS-COV2 infection cases where symptoms began between February 22th, 2020, and April 18th, 2021, as published by the General Epidemiology Direction (DGE) of the Mexican Ministry of Health. We calculated COVID-19 incidence and mortality by age group using population data from the Statistics and Population National Institute (INEGI), and estimated the association between risk of death and the presence of comorbidities.Results Mortality in SARS-COV2 infected people varied considerably, between 7 to 155 deaths per million per year in the under-20 age groups compared to 441 to 15,929 in the older age groups. Mortality in pediatric populations is strongly associated with comorbidities (OR: 4.6-47.9) compared to the milder association for older age groups (OR: 3.16-1.23).Conclusions The risk of death from SARS-COV2 infection in children is low and is strongly associated with comorbidities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for the elaboration o this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Appropriate research reporting guidelines has been folled. This is an analysis of a secondary source, available as open data from de Ministry of Health. So no IRB approval was needed,All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available at https://www.gob.mx/salud/documentos/datos-abiertos-152127 https://www.gob.mx/salud/documentos/datos-abiertos-152127 ER -